Seminars in Pediatric Neurology
Volume 15, Issue 3 , Pages 119-126 , September 2008

Current Strategies in the Management of Lysosomal Storage Diseases

  • Bryce A. Heese, MA, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Bryce A. Heese, MA, MD, Department of Pediatrics, PO Box 100296, Gainesville, FL 32610

References 

  1. Peters C, Steward C. Haematopoietic cell transplantation for inherited metabolic diseases: An overview of outcomes and practice guidelines. Bone Marrow Transplant. 2003;31:229–239
  2. Hobbs J, Hugh-Jones K, Barrett A, et al. Reversal of clinical features of Hurler's disease and biochemical improvements after treatment by bone-marrow transplantation. Lancet. 1981;2:709–712
  3. Rovelli A, Steward C. Haematopoietic cell transplantation activity in Europe for inherited metabolic diseases: Open issues and future directsions. Bone Marrow Transplant. 2005;35:S23–S26
  4. Boelens J. Trends in haematopoietic cell transplantation for inborn errors of metabolism. J Inherit Metab Dis. 2006;29:413–420
  5. Beck M. New therapeutic options for lysosomal storage disorders: Enzyme replacement, small molecules and gene therapy. Hum Genet. 2007;121:1–11
  6. Peters C, Balthazor M, Shapiro E, et al. Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood. 1996;87:4894–4902
  7. Escbolar M, Poe M, Provenzale J, et al. Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. N Engl J Med. 2006;352:2069–2081
  8. Krivit W. Allogeneic stem cell transplantation for the treatment of lysosomal and peroxisomal metabolic disease. Semin Immunol. 2004;26:119–132
  9. Hoogerbrugge P, Brouwer O, Bordigoni P, et al. Allogeneic bone marrow transplantation for lysosomal storage diseases (The European Group for Bone Marrow Transplantation). Lancet. 1995;345:1398–1402
  10. Martin P, Carter S, Kernan N, et al. Results of the cord blood transplantation sticy (COBLT): Outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with lysosomal and peroxisomal storage diseases. Biol Blood Marrow Transplant. 2006;12:184–194
  11. Fratantoni J, Hall C, Neufeld E. Hurler and Hunter syndromes: Mutual correction of the defect in cultured fibroblasts. Science. 1968;162:570–572
  12. Van der Ploeg A, Kroos M, Willemsen R, et al. Intravenous administration of phosphorylated acid alpha-glucosidase leads to uptake of enzyme in heart and skeletal muscle of mice. J Clin Invest. 1991;87:513–518
  13. Barton N, Brady R, Dambrosia J, et al. Replacement therapy for inherited enzyme deficiency—Macrophage-targeted glucocerebrosidase for Gaucher disease. N Engl J Med. 1991;324:1464–1470
  14. Grabowski G, Barton N, Pastores G, et al. Enzyme therapy in type 1 Gaucher disease: Comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med. 1995;122:33–39
  15. Migita M, Hamada H, Fujimujra J, et al. Glucocerebrosidase level in the cerebrospinal fluid during enzyme replacement therapy—Unsuccessful treatment of the neurological abnormality in type 2 Gacucher disease. Eur J Pediatr. 2003;162:524–525
  16. MacDermot K, Homes A, Miners A, et al. Natural history of Fabry disease in affected males and obligate female carriers. J Inherit Metab Dis. 2001;24(suppl 2):24-24
  17. Ramaswami U, Wendt S, Pintos-Morell G, et al. Enzyme replacement therapy with agalsidase alfa in children with Fabry disease. Acta Paediatr. 2007;96:122–127
  18. Banikazemi M, Bultas J, Waldeck S, et al. Agalsidase-beta therapy for advanced Fabry disease: A randomized trial. Ann Intern Med. 2007;146:77–86
  19. Wraith J, Clarke L, Beck M, et al. Enzyme replacement therapy for mucopolysaccharidosis I: A randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr. 2004;144:581–588
  20. Harmatz P, Giugliani R, Schwartz I, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extention study. J Pediatr. 2006;148:533–539
  21. Kishnani P, Corzo D, Nicolino M, et al. Recombinant human acid alpha-glucosidase: Major clinical benefits in infantile-onset Pompe disease. Neurology. 2007;68:99–109
  22. Muenzer J, Wraith J, Beck M, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfatase in mucopolysaccharidosis II (Hunter syndrome). Genet Med. 2006;8:465–473
  23. Wraith J. Limitations of enzyme replacement therapy: current and future. J Inherit Metab Dis. 2006;29:442–447
  24. Wilcox W. Lysosomal storage disorders: The need for better pediatric recognition and comprehensive care. J Pediatr. 2004;144:S3–S14
  25. Burrow T, Hopkin R, Leslie N, et al. Enzyme reconstitiution/replacement therapy for lysosomal storage diseases. Curr Opin Pediatr. 2007;18:628–635
  26. Dickson P, McEntee M, Vogler C, et al. Intrathecal enzyme replacement therapy: Successful treatment of brain disease via the cerebrospinal fluid. Mol Genet Metab. 2007;91:61–68
  27. Beutler E. Lysosomal storage diseases: Natural history and ethical and economic aspects. Mol Genet Metab. 2006;88:208–215
  28. Bernier V, Lagace M, Bichet D, et al. Pharmacological chaperones: Potential treatment for conformational diseases. Trends Endocrinol Metab. 2004;15:222–228
  29. Aerts J, Hollak C, Boot R, et al. Substrate reduction therapy of glycosphingolipid storage disorders. J Inherit Metab Dis. 2006;29:449–456
  30. Cox T, Aerts J, Adria G, et al. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a postion statement. J Inherit Metab Dis. 2003;26:513–526
  31. Patterson MC, Vecchio D, Prady H, et al. Miglustat for treatment of Niemann-Pick C disease: A randomized control study. Lancet. 2007;6:765–772
  32. Jakobkiewicz-Banecka J, Wegrzyn A, Wegrzyn G. Substrate deprivation therapy: A new hope for patients suffering from neuronopathic forms of inherited lysosomal storage diseases. J Appl Genet. 2007;48:383–388
  33. Dunbar C, Kohn D, Schiffmann R, et al. Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease: In vitro detection of transduced cells without myeloablation. Hum Gene Ther. 1998;9:2629–2640
  34. Raper S, Chimule N, Lee F, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab. 2003;80:148–158
  35. Kohn D, Sadelain M, Glorioso J. Occurrence of leukaemia following gene therapy of X-linked SCID. Nat Rev Cancer. 2003;3:477–488
  36. Marsden D, Larson C, Levy H. Newborn screening for metabolic disorders. J Pediatr. 2006;148:577–584
  37. National Newborn Screening & Genetics Resource Center. http://genes-r-us.uthscsa.edu2008;Accessed August 30, 2008
  38. Gelb M, Turecek F, Scot CR, et al. Direct multiplex assay of enzymes in dried blood spots by tandem mass spectrometry for the newborn screening of lysosomal storage disorders. J Inherit Metab Dis. 2006;29:397–404
  39. Meikle P, Grasby D, Dean C, et al. Newborn screening for lysosomal storage disorders. Mol Genet Metab. 2006;88:307–314
  40. Fletcher J. Screening for lysosomal storage disorders—A clinical perspective. J Inherit Metab Dis. 2006;29:405–408
  41. Newborn Screening for Krabbe Disease. http://www.wadsworth.org/newborn/krabbe.htmAccessed August 30, 2008

 Dr Heese is supported in part by an educational grant from Genzyme Corporation.

PII: S1071-9091(08)00048-X

doi: 10.1016/j.spen.2008.05.005

Seminars in Pediatric Neurology
Volume 15, Issue 3 , Pages 119-126 , September 2008

Article Tools

* Image Usage & Resolution